Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN Filmtab) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults

X
Trial Profile

A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN Filmtab) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cethromycin; Clarithromycin
  • Indications Community-acquired pneumonia; Haemophilus infections; Pneumococcal infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Jan 2012 Results published in Antimicrobial Agents and Chemotherapy.
    • 26 Feb 2010 Biomarkers information updated
    • 03 Dec 2008 NDA accepted for filing by FDA supported by data from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top